MTIC

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Retrieved on: 
Wednesday, April 10, 2024
Receptor (biochemistry), Cancer, Safety, Breast, MD, PET/CT, Patient, Neoplasm, MTIC, Therapy, Medical imaging

MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.

Key Points: 
  • MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.
  • The Phase 1 dosimetry trial is evaluating the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancer.
  • “The Monopar team is quite excited about this trial initiation,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • We are very much looking forward to seeing the biodistribution and dosimetry data from this first-in-human study in advanced cancer patients.”
    Further information about the MNPR-101-Zr trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
Thursday, March 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Retrieved on: 
Tuesday, February 27, 2024
Cancer, Glomus tumor, MD, International Cancer Imaging Society, Society, Therapy, Peter, Patient, Radiopharmaceutical, Molecular imaging, MTIC, MBBS, Pancreatic cancer, Research, PET/CT, Prostate cancer, Medical imaging

“We are very excited to have Professor Hicks as the lead investigator for our MNPR-101-Zr clinical trial,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

Key Points: 
  • “We are very excited to have Professor Hicks as the lead investigator for our MNPR-101-Zr clinical trial,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • In 2023, Professor Hicks received the Saul Hertz Award from the Society of Nuclear Medicine and Molecular Imaging for his lifetime contribution to radionuclide therapy.
  • “The preclinical data that Monopar announced on this past Thursday encourages us to translate this class of agents into the clinical domain.
  • MNPR-101-Zr is being developed for cancers with very high unmet medical need, such as pancreatic cancer and triple negative breast cancer,” said Professor Hicks.

MIM Software Celebrates MTIC's First Total-Body PET/CT Scanner

Retrieved on: 
Thursday, April 13, 2023
Partnership, International business development, Cancer, MIM, Software, Siemens Healthineers, Patient, MTIC, PET/CT, International business, Contour, Health, Disease, Medical imaging

CLEVELAND, April 12, 2023 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging software, is proud to support the efforts of the Melbourne Theronastic Innovation Centre (MTIC) in Melbourne, Victoria as they launch the use of the Siemens Biograph Vision Quadra PET/CT, one of the few such "all-organ" scanners in the world.

Key Points: 
  • The Melbourne Theronastic Innovation Centre, in partnership with Siemens Healthineers and MIM Software, will provide patients with access to a platform that will facilitate faster prognosis and personalized therapy using the world's most sensitive whole-body PET/CT scanner.
  • In this regard, MIM Software is excited to serve as the backbone for the enterprise's diagnostic and therapeutic decision pathway.
  • MTIC will be supported by MIM Encore® and MIM SurePlan™ MRT at an enterprise level, facilitating AI-based tumor identification and segmentation using Contour ProtégéAI™ and voxel-based dosimetry for accurate analysis of the dosimetric impact throughout a patient's treatment regimen.
  • I can't imagine looking at these data without the powerful software provided by MIM and look forward to partnering with their fantastic team in further enhancing our ability to extract information that better informs patient care."

ICPO Foundation and PreMIT Enter Strategic Partnership to Develop a Network of Precision Oncology and Theranostic Centers

Retrieved on: 
Monday, November 28, 2022
Technology, Research, Other Technology, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, MTIC, ICPO, Diagnosis, Use, Acceleration, Nuclear medicine, Physician, Patient, Education, Precision, Running, Cancer, Research, Radiopharmaceutical, Proprietary company, International Center for Ethnobotanical Education, Research and Service, Medical imaging, Medicine

The International Centers for Precision Oncology (ICPO) Foundation and Melbourne-based PreMIT Pty Ltd (PreMIT), today announced a collaboration to develop a global network of Precision Oncology and Theranostics centers.

Key Points: 
  • The International Centers for Precision Oncology (ICPO) Foundation and Melbourne-based PreMIT Pty Ltd (PreMIT), today announced a collaboration to develop a global network of Precision Oncology and Theranostics centers.
  • Through their joint efforts, the parties intend to scale access to Radiomolecular Precision Oncology for cancer patients globally and to foster research & industry partnerships.
  • ICPO and PreMIT have signed an agreement to establish new Theranostic centers that deliver on those key principles.
  • The network of Theranostic centers will help bridge the gap between research and improved patient access while also facilitating the development of novel radiopharmaceuticals.

Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients

Retrieved on: 
Monday, June 27, 2022
Diagnosis, Nuclear medicine, Patient, Heart, CEO, Head, NMSC, Radionuclide, Goal, MTIC, Avion, Skin, Radium, Face, Scar, Risk, Skin cancer, Partnership, Therapy, Radiation, Veni, vidi, vici, Quality of life, Canadian International Council, Incidence, Fear, AMSC, Physician, Rhenium, Forward-looking statement, Medical device, Medical imaging

MELBOURNE, Australia, June 27, 2022 /PRNewswire/ --Avion Medical Skin Centres (AMSC) have entered into an agreement with OncoBeta GmbH to treat non-melanoma skin cancer (NMSC) patients in Australia, with the new, non-invasive [1] [2] Rhenium-SCT.

Key Points: 
  • MELBOURNE, Australia, June 27, 2022 /PRNewswire/ --Avion Medical Skin Centres (AMSC) have entered into an agreement with OncoBeta GmbH to treat non-melanoma skin cancer (NMSC) patients in Australia, with the new, non-invasive [1] [2] Rhenium-SCT.
  • We are extremely excited for this partnership with Avion Medical Skin Centres and continuing to support physicians involved in the diagnosis and treatment of NMSCs."
  • Avion Medical Skin Centres offers NMSC sufferers a highly effective [2] treatment option that removes the fear and hesitation some patients may feel around aesthetic outcomes or loss of function.
  • For more information about Avion Medical Skin Centres please visit www.avionmedicalskin.com.au or for more information about OncoBeta and Rhenium-SCT please visit: www.oncobeta.com .

Millennium Corporation Opens Nations' First Threat Informatics Center, an Innovation Hub Converging Cyber Operations and Training

Retrieved on: 
Monday, September 27, 2021
Informatics, Red team, Software engineering, Water, Student, Multimedia, Bridge Street Town Centre, United States Department of Defense, Intelligence, View, Research, GPU, CTOC, R, Foot, AL, Millennium, Engineering, MTIC, Risk management

HUNTSVILLE, Ala., Sept. 27, 2021 /PRNewswire/ -- This week, Millennium Corporation unveils its new Threat Informatics Center (MTIC), a 10,000 square foot innovation hub located in Huntsville, AL that combines the capabilities of a cyber operations center, with the resources of a dedicated training center.

Key Points: 
  • HUNTSVILLE, Ala., Sept. 27, 2021 /PRNewswire/ -- This week, Millennium Corporation unveils its new Threat Informatics Center (MTIC), a 10,000 square foot innovation hub located in Huntsville, AL that combines the capabilities of a cyber operations center, with the resources of a dedicated training center.
  • The MTIC brings together multiple pillars of cybersecurity under one roof and showcases Millennium's advancements in cyber operations, technical security training, and software engineering.
  • The MTIC features over 2,000 square feet of cyber operations training and event space; a dedicated, fully equipped Cyber Threat Operations Center (CTOC); research and development labs; and multiple conference areas.
  • As home to Millennium's own Red Team Training Program, the cyber operations training facility is capable of hosting three separate, concurrent training sessions and has single-room capacity for over fifty people.